Patents by Inventor Thomas Glanmor Davies
Thomas Glanmor Davies has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10364256Abstract: The present invention relates to biaryl pyrazole compounds of Formula (I) methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.Type: GrantFiled: October 6, 2016Date of Patent: July 30, 2019Assignees: GlaxoSmithKline Intellectual Property Development Limited, Astex Therapeutics LimitedInventors: James Callahan, Jeffrey K. Kerns, Peng Li, Tindy Li, Brent W. McCleland, Hong Nie, Joseph E. Pero, Thomas Glanmor Davies, Maria Grazia Carr, Charlotte Mary Griffiths-Jones, Thomas Daniel Heightman, David Norton, Marinus Leendert Verdonk, Alison Jo-Anne Woolford, Hendrika Maria Gerarda Willems
-
Patent number: 10351530Abstract: The present invention relates to arylcyclohexyl pyrazole compounds of Formula (I) methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.Type: GrantFiled: October 6, 2016Date of Patent: July 16, 2019Assignees: GlaxoSmithKline Intellectual Property Development Limited, Astex Therapeutics LimitedInventors: James Callahan, Jeffrey K. Kerns, Tindy Li, Brent W. McCleland, Hong Nie, Joseph E. Pero, Thomas Glanmor Davies, Charlotte Mary Griffiths-Jones, Thomas Daniel Heightman, Steven Howard, David Norton, Marinus Leendert Verdonk, Alison Jo-Anne Woolford
-
Publication number: 20190002454Abstract: The present invention relates to bis aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.Type: ApplicationFiled: September 6, 2018Publication date: January 3, 2019Inventors: Jeffrey Charles BOEHM, Thomas Glanmor DAVIES, Alison Jo-Anne WOOLFORD, Charlotte Mary GRIFFITHS-JONES, Hendrika Maria Gerarda WILLEMS, David NORTON, Gordon SAXTY, Thomas Daniel HEIGHTMAN, Tindy LI, Jeffrey K. KERNS, Roderick S. DAVIS, Hongxing YAN
-
Patent number: 10144731Abstract: The present invention relates to bis aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.Type: GrantFiled: December 17, 2014Date of Patent: December 4, 2018Assignees: GlaxoSmithKline Intellectual Property Development Limited, Astex Therapeutics, LtdInventors: Thomas Glanmor Davies, Alison Jo-anne Woolford, Hendrika Maria Gerarda Willems, David Norton, Thomas Daniel Heightman, Jeffrey K. Kerns
-
Publication number: 20180282349Abstract: The present invention relates to biaryl pyrazole compounds of Formula (I) methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.Type: ApplicationFiled: October 6, 2016Publication date: October 4, 2018Inventors: James CALLAHAN, Jeffrey K. KERNS, Peng LI, Tindy LI, Brent W. McCLELAND, Hong NIE, Joseph E. PERO, Thomas Glanmor DAVIES, Maria GRAZIA CARR, Charlotte Mary GRIFFITHS-JONES, Thomas Daniel HEIGHTMAN, David NORTON, Marinus Leedert VERDONK, Alison Jo-Anne WOOLFORD, Hendrika Maria Gerarda WILLEMS
-
Publication number: 20180282283Abstract: The present invention relates to arylcyclohexyl pyrazole compounds of Formula (I) methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.Type: ApplicationFiled: October 6, 2016Publication date: October 4, 2018Inventors: James CALLAHAN, Jeffrey K. KERNS, Tindy LI, Brent W. McCLELAND, Hong NIE, Joseph E. PERO, Thomas Glanmor DAVIES, Charlotte Mary GRIFFITHS-JONES, Thomas Daniel HEIGHTMAN, Steven HOWARD, David NORTON, Marinus Leendert VERDONK, Alison Jo-Anne WOOLFORD
-
Publication number: 20160318917Abstract: The present invention relates to bis aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.Type: ApplicationFiled: December 17, 2014Publication date: November 3, 2016Inventors: Jeffrey Charles Boehm, Thomas Glanmor Davies, Alison Jo-anne Woolford, Charlotte Mary Griffiths-Jones, Hendrika Maria Gerarda Willems, David Norton, Gordon Saxity, Thomas Daniel Heightman, Tindy Li, Jeffrey K. Kerns, Roderick S. Davis, Hongxing Yan
-
Patent number: 8796293Abstract: The invention provides a compound of the formula (I) or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR5; J1-J2 is N?C(R6), (R7)C?N, (R8)N—C(O), (R8)2C—C(O), N?N or (R7)C?C(R6); E is a monocyclic carbocyclic or heterocyclic group of 5 or 6 ring members, the heterocyclic group containing up to 3 heteroatoms selected from O, N and S; Q1 is a bond or a saturated C1-3 hydrocarbon linker group, one of the carbon atoms in the linker group being optionally be replaced by an oxygen or nitrogen atom, or an adjacent pair of carbon atoms may be replaced by CONRq or NRqCO where Rq is hydrogen or methyl, or Rq is a C1-4alkylene chain linked to R1 or a carbon atom of Q1 to form a cyclic moiety; and wherein the carbon atoms of the linker group Q1 may optionally bear one or more substituents selected from fluorine and hydroxy; Q2 is a bond or a saturated hydrocarbon linker group containing from 1 to 3 carbon atoms, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygeType: GrantFiled: April 25, 2007Date of Patent: August 5, 2014Assignees: Astex Therapeutics Limited, The Institute of Cancer Research: Royal Cancer Hospital, Cancer Research Technology LimitedInventors: Thomas Glanmor Davies, Michelle Dawn Garrett, Robert George Boyle, Ian Collins
-
Patent number: 8343953Abstract: The invention provides compounds of the formula (I) having ROCK kinase and/or protein kinase p70S6K inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R1 and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom ? with respect to the NR2R3 group and provided that the oxo group when present is located at a carbon atom ? with respect to the NR2R3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R1 is an aryl or heteroaryl group; and R2, R3, R4 and R5 are as defined in the claims.Type: GrantFiled: June 21, 2006Date of Patent: January 1, 2013Assignees: Astex Therapeutics Limited, The Institute of Cancer Research: Royal Cancer Hospital, Cancer Research Technology LimitedInventors: Thomas Glanmor Davies, Robert George Boyle, Ian Collins, Michelle Dawn Garrett
-
Publication number: 20100130464Abstract: The invention provides compounds of the formula (I) having ROCK kinase and/or protein kinase p70S6K inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R1 and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR2R3 group and provided that the oxo group when present is located at a carbon atom ? with respect to the NR2R3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R1 is an aryl or heteroaryl group; and R2, R3, R4 and R5 are as defined in the claims.Type: ApplicationFiled: June 21, 2006Publication date: May 27, 2010Applicants: ASTEX THERAPEUTICS LIMITED, The Institute of Cancer Research: Royal Cancer Hospital, Cancer Research Technology LimitedInventors: Thomas Glanmor Davies, Robert George Boyle, Ian Collins, Michelle Dawn Garrett
-
Publication number: 20100022564Abstract: The invention provides a compound of the formula (I) or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR5; J1-J2 is N?C(R6), (R7)C?N, (R8)N—C(O), (R8)2C—C(O), N?N or (R7)C?C(R6); E is a monocyclic carbocyclic or heterocyclic group of 5 or 6 ring members, the heterocyclic group containing up to 3 heteroatoms selected from O, N and S; Q1 is a bond or a saturated C1-3 hydrocarbon linker group, one of the carbon atoms in the linker group being optionally be replaced by an oxygen or nitrogen atom, or an adjacent pair of carbon atoms may be replaced by CONRq or NRqCO where Rq is hydrogen or methyl, or Rq is a C1-4alkylene chain linked to R1 or a carbon atom of Q1 to form a cyclic moiety; and wherein the carbon atoms of the linker group Q1 may optionally bear one or more substituents selected from fluorine and hydroxy; Q2 is a bond or a saturated hydrocarbon linker group containing from 1 to 3 carbon atoms, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygeType: ApplicationFiled: April 25, 2007Publication date: January 28, 2010Applicants: ASTEX THERAPEUTICS LIMITED, THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL, CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Thomas Glanmor Davies, Michelle Dawn Garrett, Robert George Boyle, Ian Collins
-
Publication number: 20090253718Abstract: The invention provides a compound having the formula (I): or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR5; J1-J2 is N?C(R6), (R7)C?N, (R8)N—C(O), (R8)2C—C(O), N?N or (R7)C?C(R6); A is an optionally substituted saturated C1-7 hydrocarbon linker group having a maximum chain length of 5 atoms extending between R1 and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, one of the carbon atoms in the linker group being optionally replaced by oxygen or nitrogen; E is a monocyclic or bicyclic carbocyclic or heterocyclic group or an acyclic group X-G wherein X is CH2, O, S or NH and G is a C1-4 alkylene chain wherein one of the carbon atoms is optionally replaced by O, S or NH; R1 is hydrogen or an aryl or heteroaryl group; R2 and R3 are each hydrogen, optionally substituted C1-4 hydrocarbyl or optionally substituted C1-4 acyl; or NR2R3 forms an imidazole group or a saturated monocyclic heterocyclic group having 4-7 ring members; or NR2R3 and A together form a saturType: ApplicationFiled: April 25, 2007Publication date: October 8, 2009Applicants: Astex Therapeutics Limited, The Institute of Cancer Research: Royal Cancer Hospital, Cancer Research Technology LimitedInventors: Thomas Glanmor Davies, Michelle Dawn Garrett, Robert George Boyle, Ian Collins